Stemline therapeutics inc (STML)
Income statement / TTM
Mar'20Dec'19Sep'19Jun'19Mar'19Dec'18Sep'18Jun'18Mar'18Dec'17Sep'17Jun'17Mar'17Dec'16Sep'16Jun'16Mar'16Dec'15Sep'15Jun'15Mar'15Dec'14Sep'14Jun'14Mar'14Dec'13Sep'13Jun'13Mar'13Dec'12Sep'12Jun'12Mar'12
Income:
Cost of goods sold

5,448

4,893

0

0

0

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

Research and development

45,313

50,724

52,252

51,678

51,970

47,725

52,375

53,035

53,330

50,242

40,801

35,560

30,957

27,869

28,468

28,632

29,955

29,458

26,629

24,268

20,159

21,240

21,795

20,139

20,133

16,178

11,112

9,009

5,773

3,376

0

0

0

Selling, general and administrative

69,434

66,846

65,223

59,456

49,077

39,061

29,421

23,927

19,785

19,214

17,143

16,178

14,558

12,056

11,545

10,592

9,884

8,828

8,235

8,020

7,906

8,084

8,425

8,659

7,692

7,871

6,264

4,957

4,868

3,090

0

0

0

Total operating expenses

120,196

122,464

119,216

111,803

101,133

86,786

81,797

76,962

73,115

69,456

57,944

51,739

45,516

39,926

40,014

39,225

39,840

38,287

34,865

32,288

28,065

29,325

30,221

28,799

27,826

24,050

17,376

13,967

10,642

6,467

0

0

0

Loss from operations

-73,155

-79,247

-87,828

-93,748

-95,584

-86,286

-81,297

-76,162

-72,516

-68,558

-56,746

-50,541

-44,380

-38,885

-39,066

-38,371

-39,102

-37,633

-34,295

-31,853

-27,679

-28,989

-29,936

-28,585

-27,684

-23,979

-17,376

-13,967

-10,642

-6,467

0

0

0

Other expense, net

-58

-47

-16

-15

-15

-7

7

0

0

-

0

-

-

-

-

-

-

-

-

-

-

-

-

-

0

-

-

-

124

0

0

0

0

Other Income

-

-

-

-

-

-

-

-

-

-

0

-

-

-

0

0

-

-

4

5

0

-

0

0

-

280

54

319

331

301

0

0

0

Interest expense

0

-

-

-

0

-

0

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

516

544

449

179

118

0

0

0

Interest income

2,642

2,538

2,050

1,807

1,575

1,270

1,166

1,022

847

736

672

586

523

545

545

551

486

387

289

192

159

156

129

93

0

-

0

0

-

9

0

0

0

Net loss before income taxes

-70,640

-76,791

-85,785

-91,949

0

-

-

0

-

-

-

-

-

-

0

0

-

-37,243

-33,996

-31,648

-27,507

-28,829

-29,564

-28,252

-27,690

-24,196

-17,859

-14,215

-10,610

-6,274

0

0

0

Income tax (expense) benefit

11

-25

-13

-22

0

-

-

-

-

-

-

-

-

-

0

0

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

Net loss

-70,703

-76,817

-85,772

-91,927

-94,014

-85,024

-80,138

-75,150

-71,679

-67,828

-56,088

-49,955

-43,820

-38,303

-37,526

-37,757

0

-

0

0

-

-

-

-

-

-

0

0

0

-

0

0

0

Net loss per common share:
Basic and Diluted (in dollars per share)

-0.45

-0.34

-0.34

-0.42

-0.73

-0.91

-0.73

-0.66

-0.69

-0.93

-0.68

-0.66

-0.67

-0.56

-0.56

-0.52

-0.51

-0.58

-0.53

-0.58

-0.46

-0.53

-0.53

-0.47

-0.70

-0.45

-0.45

-0.55

-0.90

-

-0.56

-0.54

-

Weighted-average shares outstanding:
Basic and Diluted (in shares)

47,674

46,971

43,733

40,108

37,550

29,123

29,018

28,567

26,845

23,540

23,464

23,412

21,810

17,886

17,831

17,785

17,716

17,559

17,515

17,497

16,582

12,999

12,950

12,921

12,875

12,813

12,471

9,837

6,147

-

3,441

3,441

-

Basic (in dollars per share)

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-0.34

Diluted (in dollars per share)

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-0.34

Basic (in shares)

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

3,441

Diluted (in shares)

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

3,441

Product revenue, net
Revenue

47,040

43,216

31,887

0

0

-

-

0

-

898

1,197

1,197

1,135

1,041

947

853

738

654

569

435

385

335

0

0

0

-

-

-

-

-

-

-

-